Regeneron Pharmaceuticals Inc (REGN)
738.00
-6.50
(-0.87%)
USD |
NASDAQ |
Nov 22, 16:00
739.98
+1.98
(+0.27%)
After-Hours: 20:00
Regeneron Pharmaceuticals Cash from Investing (Quarterly): -574.40M for Sept. 30, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -574.40M |
| June 30, 2024 | -557.20M |
| March 31, 2024 | -1.687B |
| December 31, 2023 | -66.20M |
| September 30, 2023 | -496.30M |
| June 30, 2023 | -2.387B |
| March 31, 2023 | -235.70M |
| December 31, 2022 | -1.858B |
| September 30, 2022 | 192.30M |
| June 30, 2022 | -413.90M |
| March 31, 2022 | -1.705B |
| December 31, 2021 | -2.013B |
| September 30, 2021 | -2.439B |
| June 30, 2021 | 125.80M |
| March 31, 2021 | -1.059B |
| December 31, 2020 | -305.00M |
| September 30, 2020 | -775.80M |
| June 30, 2020 | 1.453B |
| March 31, 2020 | -443.20M |
| December 31, 2019 | -208.70M |
| September 30, 2019 | -207.00M |
| June 30, 2019 | -836.00M |
| March 31, 2019 | -776.10M |
| December 31, 2018 | -265.90M |
| September 30, 2018 | -286.70M |
| Date | Value |
|---|---|
| June 30, 2018 | -485.00M |
| March 31, 2018 | -425.40M |
| December 31, 2017 | -335.76M |
| September 30, 2017 | -358.88M |
| June 30, 2017 | -170.41M |
| March 31, 2017 | -140.14M |
| December 31, 2016 | -271.25M |
| September 30, 2016 | -405.85M |
| June 30, 2016 | -326.01M |
| March 31, 2016 | -43.68M |
| December 31, 2015 | -123.30M |
| September 30, 2015 | -283.17M |
| June 30, 2015 | -371.65M |
| March 31, 2015 | -129.48M |
| December 31, 2014 | 56.64M |
| September 30, 2014 | -123.07M |
| June 30, 2014 | -118.12M |
| March 31, 2014 | -236.23M |
| December 31, 2013 | -109.95M |
| September 30, 2013 | -214.45M |
| June 30, 2013 | 116.63M |
| March 31, 2013 | -147.68M |
| December 31, 2012 | 91.10M |
| September 30, 2012 | -48.75M |
| June 30, 2012 | -139.19M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-2.439B
Minimum
Sep 2021
1.453B
Maximum
Jun 2020
-772.62M
Average
-526.75M
Median
Cash from Investing (Quarterly) Benchmarks
| Amgen Inc | -210.00M |
| Eli Lilly and Co | -4.005B |
| Pfizer Inc | -2.057B |
| Biogen Inc | -1.181B |
| AbbVie Inc | -8.256B |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 1.291B |
| Cash from Financing (Quarterly) | -634.00M |
| Free Cash Flow | 3.319B |
| Free Cash Flow Per Share (Quarterly) | 9.030 |
| Free Cash Flow to Equity (Quarterly) | 1.049B |
| Free Cash Flow to Firm (Quarterly) | 1.049B |
| Free Cash Flow Yield | 3.91% |